Welcome to our dedicated page for PERRIGO COMPANY PLC news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on PERRIGO COMPANY PLC stock.
Perrigo Company plc (NYSE: PRGO) is a leading global provider of over-the-counter (OTC) consumer goods and pharmaceutical products, delivering high-quality healthcare solutions at affordable prices. Established in 1887, Perrigo has grown from a packager of generic home remedies to a top-five global OTC manufacturer and supplier of store-brand infant formulas. Headquartered in Ireland, Perrigo operates across North America, Europe, Australia, Israel, and China.
Perrigo's diverse product portfolio includes private-label consumer health goods sold to major retailers such as Walmart, Amazon, Costco, and CVS. In addition, the company offers branded OTC products, generic extended topical prescription products, and receives royalties from the multiple sclerosis drug Tysabri®.
In recent years, Perrigo has focused on expanding its consumer self-care business. A significant milestone was the FDA approval of Opill®, the first-ever daily birth control pill available OTC in the U.S., which Perrigo began shipping in March 2024. The company's strategic initiatives also include Project Energize, a growth and efficiency program aimed at driving sustainable, value-accretive growth.
Perrigo continues to make strides in the industry, as evidenced by its financial performance and strategic partnerships. The company reported net sales of $1.1 billion for the first quarter of 2024, despite facing challenges such as inventory de-stocking at U.S. retail customers and supply chain constraints. Perrigo's leadership team, including the recent appointment of Roberto Khoury to lead the Consumer Self-Care International segment, is committed to driving innovation and expanding the company's global footprint.
For more information, visit Perrigo's website.
Perrigo Company plc (NYSE: PRGO) announced the launch of syndication for new senior secured credit facilities totaling approximately $1.6 billion. This comprises a $1 billion revolving credit facility and $1.1 billion in term loans. The funds will be used to finance its acquisition of Héra SAS and refinance existing debt. The agreement involves major financial institutions, including JPMorgan Chase and Morgan Stanley. However, completion is subject to market conditions, and there is no guarantee of execution on anticipated terms.
Perrigo Company plc (NYSE: PRGO) announced the upcoming retirement of CFO Ray Silcock, effective July 15, 2022. The company will conduct a comprehensive search for his successor. Silcock played a key role in transforming Perrigo into a consumer self-care company since March 2019, leading significant initiatives such as acquiring and divesting nine businesses. CEO Murray Kessler praised Silcock for his contributions, ensuring a smooth transition. Perrigo, a leading provider of consumer self-care products, aims to empower individuals through affordable health solutions.
Perrigo Company plc (NYSE: PRGO) has received final FDA approval for the over-the-counter use of Nasonex® 24HR Allergy (mometasone furoate monohydrate 50mcg). This marks the company’s first Rx-to-OTC switch, set to enhance its product offerings and strengthen its market presence. Perrigo plans to launch Nasonex® later this year, aiming to provide consumers with quality self-care options. This approval underscores Perrigo's commitment to innovation in self-care products, potentially increasing revenue through expanded market access.
Perrigo Company plc (NYSE: PRGO) has finalized the sale of its over-the-counter (OTC) businesses in Mexico and Brazil to Advent International. This move is part of Perrigo's margin improvement program and Project Momentum initiative. The divestiture, which generated $98 million in net sales in 2021, is expected to have a minimal impact on adjusted diluted earnings per share for 2022. Perrigo aims to strengthen its consumer self-care strategy and improve operational efficiencies through this transaction.
Perrigo Company reported a 4.9% increase in fourth quarter net sales to $1.1 billion, with 5.7% growth excluding currency effects, driven by rising demand for cough/cold products. Fiscal year 2021 net sales totaled $4.1 billion, a 1.2% rise, impacted by a 0.3% decline from currency. Fourth quarter GAAP diluted EPS was $0.24, reversing a loss of $0.39 from last year. The company achieved major strategic goals, including divesting its generic RX segment, acquiring HRA Pharma, and settling its Irish tax issues, positioning for future growth despite challenges from COVID-19 and supply chain disruptions.
Perrigo Company plc (NYSE: PRGO) announced that CEO Murray S. Kessler and CFO Ray Silcock will present at the Raymond James 43rd Annual Institutional Investors Conference at 11:00 AM EST on March 8 in Orlando, Florida. Kessler will also present at the UBS Global Consumer and Retail Conference at 1:00 PM EST on March 9 in Boston, Massachusetts. Webcasts of both presentations will be available on Perrigo's website. Perrigo is a leading provider of self-care products, being the largest store brand OTC player in the U.S.
Perrigo Company plc (NYSE: PRGO) announced a 7% increase in its quarterly dividend to $0.26 per share, up from $0.24 per share. This marks the 19th consecutive year of dividend increases. The cash dividend is payable on March 17, 2022 to shareholders of record by February 28, 2022, totaling $1.04 annually. Perrigo, a leader in Quality, Affordable Self-Care Products, remains committed to enhancing consumer well-being through its extensive range of over-the-counter health solutions.
Perrigo Company plc (NYSE; TASE: PRGO) is set to release its fourth quarter and fiscal year 2021 financial results on March 1, 2022, at 8:30 A.M. (EST). A conference call will follow, accessible via webcast on the Perrigo investor relations website. The company is known for its wide range of OTC health and wellness solutions, leading as a store brand OTC player in the U.S. and a top contender in Europe with over 200 branded products across 28 countries. Investors should stay tuned for updates reflecting the company's financial performance and strategic direction.
Perrigo Company plc (NYSE: PRGO) has partnered with Premise Health to enhance its occupational health program by introducing virtual health services for employees outside Michigan. This initiative, launching this month, aims to provide 24/7 access to essential occupational health care via Premise's Digital Wellness Center. Key services include injury evaluation, treatment, and return-to-work strategies. This expansion promotes employee health and aims to increase productivity while reducing healthcare costs.
Perrigo Company plc (NYSE; TASE: PRGO) announced that President and CEO, Murray S. Kessler, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 PM (EST). The virtual presentation can be accessed on the company's website. Perrigo leads in providing quality self-care products and OTC health solutions, holding over 9,000 SKUs under customer brands in the U.S. and being a top OTC company in Europe. More details are available on their website at www.perrigo.com.
FAQ
What is the current stock price of PERRIGO COMPANY PLC (PRGO)?
What is the market cap of PERRIGO COMPANY PLC (PRGO)?
What products does Perrigo Company plc offer?
Where is Perrigo Company plc headquartered?
What is Project Energize?
What is Opill®?
Who are some of Perrigo's major retail partners?
What is Perrigo's focus in the healthcare market?
What recent changes have occurred in Perrigo's leadership?
How did Perrigo perform financially in Q1 2024?
What is Perrigo's approach to innovation?
How can I learn more about Perrigo Company plc?
